Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs

Executive Summary

FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said
Advertisement

Related Content

Computer Simulations Of Clinical Trials To Be Addressed In FDA Guidance
Computer Simulations Of Clinical Trials To Be Addressed In FDA Guidance
FDA Will Publish “Critical Path” Opportunities List By Fall, Woodcock Says
FDA Will Publish “Critical Path” Opportunities List By Fall, Woodcock Says
Aventis Drug Candidate Assessment Finds Half Fail Due To Safety Concerns
Advertisement
UsernamePublicRestriction

Register

PS044019

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel